REVELATION BIOSCIENCES, INC. (REVB)
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Revelation Biosciences, Inc.
- GeminiREADOUTCash runway at this date: -5mo
Trials need funding. See this company's dilution risk and cash position.
- Phase 1/2Completed
Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease.
Intravenous Gemini, Intravenous placebo
Renal Insufficiency, Chronic, Chronic Kidney Disease stage3 +1
NCT06863467Enrollment40StartJan 2025Primary CompletionJul 2025CompletionJul 2025
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 1/2 | Completed | Intravenous Gemini, Intravenous placebo | NCT06863467 |